Non-peptide gonadotropin-releasing hormone antagonist (GnRH-antagonist) is a highly efficient and selective antagonist of GnRH receptor. The oral preparations (Elagolix, Relugolix and Linzagolix) had been approved for listing abroad. It shows efficacy in reducing the size of uterine fibroid and controlling heavy bleeding. Appropriate combination of‘add-back’therapy could improve the safety in medical application and patient compliance. Compared with other hormonal pharmaceuticals, oral GnRH-antagonists showed promising prospects in the treatment of uterine fibroid.